Citadel Advisors’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-436,900
| Closed | -$31.5M | – | 14046 |
|
|
2025
Q4 | $31.5M | Buy |
436,900
+305,900
| +234% | +$19.8M | ﹤0.01% | 1846 |
|
|
2025
Q3 | $5.71M | Buy |
131,000
+109,600
| +512% | +$4.43M | ﹤0.01% | 4126 |
|
|
2025
Q2 | $608K | Sell |
21,400
-6,200
| -22% | -$185K | ﹤0.01% | 8166 |
|
|
2025
Q1 | $815K | Buy |
27,600
+500
| +2% | +$15.6K | ﹤0.01% | 7398 |
|
|
2024
Q4 | $788K | Buy |
27,100
+7,500
| +38% | +$313K | ﹤0.01% | 7541 |
|
|
2024
Q3 | $900K | Sell |
19,600
-40,400
| -67% | -$1.75M | ﹤0.01% | 7082 |
|
|
2024
Q2 | $2.45M | Buy |
60,000
+55,900
| +1,363% | +$1.6M | ﹤0.01% | 4936 |
|
|
2024
Q1 | $105K | Sell |
4,100
-3,900
| -49% | -$61.1K | ﹤0.01% | 11300 |
|
|
2023
Q4 | $72.4K | Buy |
8,000
+6,700
| +515% | +$44.8K | ﹤0.01% | 11348 |
|
|
2023
Q3 | $8.29K | Sell |
1,300
-17,300
| -93% | -$149K | ﹤0.01% | 13202 |
|
|
2023
Q2 | $206K | Buy |
18,600
+10,300
| +124% | +$129K | ﹤0.01% | 9820 |
|
|
2023
Q1 | $127K | Sell |
8,300
-28,700
| -78% | -$631K | ﹤0.01% | 10898 |
|
|
2022
Q4 | $821K | Buy |
+37,000
| New | +$552K | ﹤0.01% | 7189 |
|
Other funds holding RNAM
Citadel Advisors's RNAM Position: Q1 2026 in Review
Citadel Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 1,592,429 shares — an estimated $115M sold.
Citadel Advisors first reported a position in RNAM in Q2 2020 and held it in 16 quarters. The position peaked at $115M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Citadel Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 1,592,429 Avidity Biosciences shares in Q1 2026, an estimated $115M.
- Citadel Advisors first reported a position in Avidity Biosciences in Q2 2020 and held it in 16 quarters.
- Citadel Advisors's Avidity Biosciences position peaked at $115M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.